MCID: TRC008
MIFTS: 54

Trachoma

Categories: Eye diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Trachoma

MalaCards integrated aliases for Trachoma:

Name: Trachoma 12 77 54 56 45 15 74
Trachoma, Initial Stage 74
Trachoma, Active Stage 74
Active Stage Trachoma 12
Trachoma Dubium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11265
MeSH 45 D014141

Summaries for Trachoma

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection located in eye, has material basis in Chlamydia trachomatis (A, B, Ba and C serovars), which is transmitted by contact with eye discharge from the infected person and transmitted by congenital method. The infection causes eyelid to turn inward which makes eyelashes to scratch the cornea.

MalaCards based summary : Trachoma, also known as trachoma, initial stage, is related to chlamydia and malaria. An important gene associated with Trachoma is KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Allograft rejection. The drugs Azithromycin and Permethrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Trachoma is an infectious disease caused by bacterium Chlamydia trachomatis. The infection causes a... more...

Related Diseases for Trachoma

Diseases related to Trachoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 chlamydia 32.1 HSPD1 IDO1 IL10 TNF
2 malaria 29.4 HLA-B IDO1 IL10 TNF
3 entropion 11.5
4 onchocerciasis 11.4
5 conjunctivitis 10.7
6 inclusion conjunctivitis 10.6
7 ornithosis 10.5
8 lymphogranuloma venereum 10.5
9 listeriosis 10.3 IDO1 TNF
10 hemorrhagic fever 10.3 IL10 TNF
11 punctate inner choroidopathy 10.3 IL10 TNF
12 sympathetic ophthalmia 10.3 HLA-C TNF
13 tropical endomyocardial fibrosis 10.3 IL10 TNF
14 endomyocardial fibrosis 10.3 IL10 TNF
15 multifocal choroiditis 10.3 IL10 TNF
16 choroiditis 10.3 IL10 TNF
17 tungiasis 10.3 IL10 TNF
18 intraocular pressure quantitative trait locus 10.3
19 yaws 10.3
20 nodular lymphocyte predominant hodgkin lymphoma 10.3
21 transient hypogammaglobulinemia 10.3 IL10 TNF
22 cow milk allergy 10.3 IL10 TNF
23 trichuriasis 10.3 IL10 TNF
24 idiopathic achalasia 10.3 IL10 TNF
25 mucocutaneous leishmaniasis 10.3 IL10 TNF
26 chronic graft versus host disease 10.3 IL10 TNF
27 clonorchiasis 10.3 IL10 TNF
28 autoimmune gastritis 10.3 IL10 TNF
29 autoimmune disease of eyes, ear, nose and throat 10.3 IL10 TNF
30 orofacial granulomatosis 10.3 IL10 TNF
31 transverse myelitis 10.3 IL10 TNF
32 post-transplant lymphoproliferative disease 10.3 IL10 TNF
33 primary systemic mycosis 10.3 IL10 TNF
34 mycoplasma pneumoniae pneumonia 10.2 IL10 TNF
35 chronic active epstein-barr virus infection 10.2 IDO1 IL10
36 multidrug-resistant tuberculosis 10.2 IL10 TNF
37 poliomyelitis 10.2 IL10 TNF
38 eales disease 10.2 IL10 TNF
39 spotted fever 10.2 IL10 TNF
40 salpingitis 10.2 HSPD1 TNF
41 coccidiosis 10.2 IL10 TNF
42 aseptic meningitis 10.2 IL10 TNF
43 plasmodium vivax malaria 10.2 IL10 TNF
44 bacterial sepsis 10.2 IL10 TNF
45 lacrimal apparatus disease 10.2 IL10 TNF
46 commensal bacterial infectious disease 10.2 IL10 TNF
47 churg-strauss syndrome 10.2 IL10 TNF
48 epstein-barr virus-associated gastric carcinoma 10.2 IL10 TNF
49 q fever 10.2 IL10 TNF
50 viral encephalitis 10.2 IL10 TNF

Graphical network of the top 20 diseases related to Trachoma:



Diseases related to Trachoma

Symptoms & Phenotypes for Trachoma

GenomeRNAi Phenotypes related to Trachoma according to GeneCards Suite gene sharing:

27 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.4 HSPD1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.4 KIR2DL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.4 HLA-C HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.4 KIR2DL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.4 HLA-C HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.4 HLA-C HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.4 KIR2DL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.4 KIR2DL2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.4 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.4 HSPD1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.4 HSPD1 KIR2DL2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.4 KIR2DL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.4 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.4 HLA-C HLA-B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.4 HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.4 KIR2DL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.4 HSPD1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.4 KIR2DL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.4 HLA-C HLA-B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.4 HLA-C HLA-B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.4 KIR2DL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.4 KIR2DL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.4 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.4 HLA-C HLA-B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.4 HLA-C
26 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.4 KIR2DL2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.4 KIR2DL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.4 HSPD1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.4 HLA-C KIR2DL2 HLA-B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.4 KIR2DL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.4 HLA-C KIR2DL2 HLA-B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.4 KIR2DL2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.4 HLA-C HSPD1 KIR2DL2

MGI Mouse Phenotypes related to Trachoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 ENG HSPD1 IDO1 IL10 TNF

Drugs & Therapeutics for Trachoma

Drugs for Trachoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
2
Permethrin Approved, Investigational Phase 4,Phase 2 52645-53-1 40326
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
5
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 70288-86-7 6474909
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Sulfamethoxazole Approved Phase 4 723-46-6 5329
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Not Applicable
11 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
12 Anthelmintics Phase 4,Phase 3,Not Applicable
13 Antimitotic Agents Phase 4,Phase 3,Not Applicable
14 Antiparasitic Agents Phase 4,Phase 3,Not Applicable
15 Antiprotozoal Agents Phase 4,Phase 3,Not Applicable
16 Antitubercular Agents Phase 4
17 Renal Agents Phase 4
18 Anti-Infective Agents, Urinary Phase 4
19 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
20 Antimalarials Phase 4
21 Vaccines Phase 4
22 Immunologic Factors Phase 4
23
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
24 Ophthalmic Solutions Phase 3,Not Applicable
25 Pharmaceutical Solutions Phase 3,Not Applicable
26 Lipoxygenase Inhibitors Phase 3
27 Insect Repellents Phase 2
28 Protective Agents Phase 2
29
Fluorometholone Approved, Investigational Not Applicable 426-13-1 9878
30 glucocorticoids Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
32 Hormone Antagonists Not Applicable
33 Hormones Not Applicable
34 Lubricant Eye Drops Not Applicable
35 Anti-Inflammatory Agents Not Applicable
36 Anti-Allergic Agents Not Applicable

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
2 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
3 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
4 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
5 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
6 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
7 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
8 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
9 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
10 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia Completed NCT00347776 Phase 4 azithromycin;topical tetracycline
11 Mortality Reduction After Oral Azithromycin: Mortality Study Completed NCT02047981 Phase 4 Azithromycin;Placebo
12 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4 Azithromycin;Tetracycline;Albendazole
13 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children Recruiting NCT02414399 Phase 4 Azithromycin;Placebo
14 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Active, not recruiting NCT03187834 Phase 4 Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
15 Mortality Reduction After Oral Azithromycin: Morbidity Study Enrolling by invitation NCT02048007 Phase 4 Azithromycin;Placebo
16 Trachoma Elimination Study by Focused Antibiotic (TESFA) Not yet recruiting NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
17 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
18 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
19 Community Health Azithromycin Trial in Burkina Faso Not yet recruiting NCT03676764 Phase 4 Azithromycin;Placebos
20 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
21 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
22 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
23 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
24 Prevention of Bacterial Infections in Newborn Completed NCT01800942 Phase 3 Azithromycin and Placebo
25 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
26 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin
27 Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Suspended NCT03813069 Phase 2
28 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed NCT01767506 Not Applicable
29 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Not Applicable Azithromycin
30 Modified Instrumentation for Surgery to Correct Trichiasis Completed NCT00886015 Not Applicable
31 Water Uptake for Health in Amhara Pilot Completed NCT02373657 Not Applicable
32 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
33 Identification of TT Cases by Community Treatment Assistants: An Assessment Completed NCT01783743 Not Applicable
34 Fluorometholone as Ancillary Therapy for TT Surgery Completed NCT01949454 Not Applicable Fluorometholone 0.1% ophthalmic solution
35 The Effect of Long-Term HEAD START Training on Surgical Skill Levels Completed NCT03135080 Not Applicable
36 A Trial of Epilation Verses Surgery for Minor Trichiasis Completed NCT00522912 Not Applicable
37 Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze Completed NCT00439114
38 Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Withdrawn NCT02655432

Search NIH Clinical Center for Trachoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: trachoma

Genetic Tests for Trachoma

Anatomical Context for Trachoma

MalaCards organs/tissues related to Trachoma:

42
Eye, Testes, T Cells, Skin, Bone, Spleen, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Trachoma:

20
Eye

Publications for Trachoma

Articles related to Trachoma:

(show top 50) (show all 1937)
# Title Authors Year
1
Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities. ( 30543311 )
2019
2
Trachoma in 3 Amerindian Communities, Venezuelan Amazon, 2018. ( 30561321 )
2019
3
Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia. ( 30674087 )
2019
4
Self-Reported Side Effects following Mass Administration of Azithromycin to Eliminate Trachoma in Amhara, Ethiopia: Results from a Region-Wide Population-Based Survey. ( 30675840 )
2019
5
Assessment of trachoma in suspected endemic areas within 16 provinces in mainland China. ( 30689647 )
2019
6
Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger. ( 30689671 )
2019
7
Sensitivity and specificity of computer vision classification of eyelid photographs for programmatic trachoma assessment. ( 30742639 )
2019
8
Factors shaping the implementation of the SAFE strategy for trachoma using the Consolidated Framework for Implementation Research: a systematic review. ( 30773102 )
2019
9
Various Manifestations Of Trachoma In Internally Displaced Rural Population - A Free Eye Camp Based Survey. ( 30868779 )
2019
10
Comments on Khokhar et al (J Pak Med Assoc. 2018; 68(9): 1300) Active trachoma among children of District Dera Ghazi Khan, Punjab, Pakistan: A cross sectional study - L ETTER TO THE EDITOR. ( 30890852 )
2019
11
Response to Comments on Khokhar et al (J Pak Med Assoc. 2018; 68(9): 1300) Active trachoma among children of District Dera Ghazi Khan, Punjab, Pakistan: A cross sectional study. ( 30890853 )
2019
12
Trachoma in Yunnan province of southwestern China: findings from trachoma rapid assessment. ( 29665861 )
2018
13
Sanitation and water supply coverage thresholds associated with active trachoma: Modeling cross-sectional data from 13 countries. ( 29357365 )
2018
14
Strengthening the links between mapping, planning and global engagement for disease elimination: lessons learnt from trachoma. ( 29907634 )
2018
15
Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with <i>Chlamydia trachomatis</i>. ( 29588922 )
2018
16
Trachoma elimination, approaching 2020. ( 29965850 )
2018
17
Prevalence of trachoma in school children in the MarajA^ Archipelago, Brazilian Amazon, and the impact of the introduction of educational and preventive measures on the disease over eight years. ( 29447155 )
2018
18
Conjunctival transcriptome profiling of Solomon Islanders with active trachoma in the absence of Chlamydia trachomatis infection. ( 29467021 )
2018
19
Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial. ( 29260659 )
2018
20
Detection of Chlamydiaceae and Chlamydia-like organisms on the ocular surface of children and adults from a trachoma-endemic region. ( 29743637 )
2018
21
Patient-centered communication of community treatment assistants in Tanzania predicts coverage of future mass drug administration for trachoma. ( 29329726 )
2018
22
Prevalence of<i>Chlamydia trachomatis</i>-Specific Antibodies before and after Mass Drug Administration for Trachoma in Community-Wide Surveys of Four Communities in Nepal. ( 29141720 )
2018
23
Meibography of Eyes With Sequelae of Trachoma. ( 29504955 )
2018
24
Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. ( 29501689 )
2018
25
Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. ( 29451881 )
2018
26
Correction: Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma. ( 29513663 )
2018
27
Population-based analysis of ocular Chlamydia trachomatis in trachoma-endemic West African communities identifies genomic markers of disease severity. ( 29482619 )
2018
28
Non-Chlamydial Bacterial Infection and Progression of Conjunctival Scarring in Trachoma. ( 29847638 )
2018
29
Prevalence of trachoma in the Kayes region of Mali eight years after stopping mass drug administration. ( 29432434 )
2018
30
Making gains sustainable: partnering with WASH to stop the transmission of trachoma. ( 29915467 )
2018
31
Baseline trachoma prevalence in Guinea: Results of national trachoma mapping in 31 health districts. ( 29889826 )
2018
32
Chlamydial ompA Diversity in Trachoma-Hyperendemic Communities Treated With Azithromycin. ( 29617922 )
2018
33
Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: A review of the grey literature. ( 29370169 )
2018
34
Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area. ( 29476106 )
2018
35
Association of Chlamydia trachomatis ompA genovar with trachoma phenotypes. ( 29503448 )
2018
36
School-Based versus Community-Based Sampling for Trachoma Surveillance. ( 29848403 )
2018
37
Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination. ( 29860288 )
2018
38
Comment on: 'Association of Chlamydia trachomatis ompA genovar with trachoma phenotypes'. ( 30390052 )
2018
39
Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem. ( 30550537 )
2018
40
Identifying a sufficient core group for trachoma transmission. ( 30296259 )
2018
41
Optimising sampling regimes and data collection to inform surveillance for trachoma control. ( 30307939 )
2018
42
Active trachoma among children of District Dera Ghazi Khan, Punjab, Pakistan: A cross sectional study. ( 30317254 )
2018
43
A systematic review of historical and contemporary evidence of trachoma endemicity in the Pacific Islands. ( 30440006 )
2018
44
Behavioural change interventions for sustained trachoma elimination. ( 30455520 )
2018
45
The History of Trachoma and Current Prevalence (Spotlight on Iran): A Review Article. ( 30524975 )
2018
46
The utility of serology for elimination surveillance of trachoma. ( 30575720 )
2018
47
Trachoma control: the SAFE strategy. ( 30588417 )
2018
48
Trachoma and Herbert's Pits. ( 30590853 )
2018
49
Impact of the Global Trachoma Mapping Project. ( 30806531 )
2018
50
Prevalence of trachoma in the area councils of the Federal Capital Territory, Nigeria: results of six population-based surveys. ( 30806532 )
2018

Variations for Trachoma

Expression for Trachoma

Search GEO for disease gene expression data for Trachoma.

Pathways for Trachoma

Pathways related to Trachoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.04 HLA-B HLA-C TNF
2
Show member pathways
11.91 HLA-B HLA-C HSPD1 IL10 KIR2DL2 KIR2DL3
3 11.89 HSPD1 IL10 TNF
4
Show member pathways
11.88 HLA-B HLA-C IL10 TNF
5
Show member pathways
11.83 HLA-B HLA-C KIR2DL2 KIR2DL3 TNF
6 11.82 HSPD1 IL10 TNF
7 11.76 HLA-B HLA-C KIR2DL2 KIR2DL3
8 11.64 ENG IL10 TNF
9 11.59 HLA-B HLA-C KIR2DL2 KIR2DL3
10 11.19 HSPD1 IL10
11 11.07 IDO1 IL10 TNF
12 11.05 IL10 TNF
13 10.96 IL10 TNF
14 10.88 HLA-B HLA-C

GO Terms for Trachoma

Cellular components related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.16 HLA-B HLA-C
2 cell surface GO:0009986 9.02 ENG HLA-B HLA-C HSPD1 TNF
3 MHC class I protein complex GO:0042612 8.96 HLA-B HLA-C

Biological processes related to Trachoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.63 IL10 TNF
2 positive regulation of interferon-gamma production GO:0032729 9.63 HSPD1 TNF
3 antigen processing and presentation GO:0019882 9.62 HLA-B HLA-C
4 negative regulation of T cell proliferation GO:0042130 9.61 IDO1 IL10
5 negative regulation of mitotic cell cycle GO:0045930 9.61 IL10 TNF
6 B cell proliferation GO:0042100 9.6 HSPD1 IL10
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.59 HLA-B HLA-C
8 negative regulation of interleukin-6 production GO:0032715 9.58 IL10 TNF
9 positive regulation of cytokine secretion GO:0050715 9.58 IL10 TNF
10 regulation of synapse organization GO:0050807 9.57 IL10 TNF
11 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.56 HLA-B HLA-C
12 positive regulation of interleukin-12 production GO:0032735 9.55 HSPD1 IDO1
13 positive regulation of T cell mediated cytotoxicity GO:0001916 9.54 HLA-B HLA-C
14 response to lipopolysaccharide GO:0032496 9.52 IDO1 IL10
15 positive regulation of macrophage activation GO:0043032 9.51 HSPD1 IL10
16 negative regulation of growth of symbiont in host GO:0044130 9.49 IL10 TNF
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.48 IL10 TNF
18 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.46 HLA-B HLA-C
19 regulation of immune response GO:0050776 9.46 HLA-B HLA-C KIR2DL2 KIR2DL3
20 response to organic substance GO:0010033 9.43 IL10 TNF
21 endothelial cell apoptotic process GO:0072577 9.4 IL10 TNF
22 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.37 HLA-B HLA-C
23 response to activity GO:0014823 9.32 IL10
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.32 IL10 TNF
25 response to glucocorticoid GO:0051384 9.26 IL10 TNF
26 immune response GO:0006955 9.02 HLA-B HLA-C IL10 KIR2DL3 TNF
27 receptor biosynthetic process GO:0032800 8.96 IL10 TNF

Molecular functions related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-C

Sources for Trachoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....